Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense first-line therapy of metastatic breast cancer with paclitaxel and liposomal doxorubicin (Myocet)
2005-004234-41Phase 2Terminated
- Sponsor
- Otto von Guericke University Magdeburg
- Start
- Mar 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and paclitaxel in breast cancer, sponsored by Otto von Guericke University Magdeburg. Primary endpoint: Time to progression. Started Mar 2008; status: terminated.
02
Drugs
doxorubicinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004234-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004234-41.